Zynex (ZYXI) News Today $7.84 -0.24 (-2.97%) Closing price 01/31/2025 04:00 PM EasternExtended Trading$7.84 0.00 (0.00%) As of 01/31/2025 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Zynex eyes FDA submission for NiCO oximeter as it expands portfolio of innovative medical devicesJanuary 28, 2025 | proactiveinvestors.comInsider Selling: Zynex, Inc. (NASDAQ:ZYXI) CFO Sells 10,000 Shares of StockJanuary 4, 2025 | insidertrades.comDaniel J. Moorhead Sells 10,000 Shares of Zynex, Inc. (NASDAQ:ZYXI) StockZynex, Inc. (NASDAQ:ZYXI - Get Free Report) CFO Daniel J. Moorhead sold 10,000 shares of the business's stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $7.88, for a total value of $78,800.00. Following the sale, the chief financial officer now owns 26,299 shares of the company's stock, valued at approximately $207,236.12. The trade was a 27.55 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.January 3, 2025 | marketbeat.comZynex (ZYXI) Gets a Buy from RBC CapitalDecember 20, 2024 | markets.businessinsider.comAn Intrinsic Calculation For Zynex, Inc. (NASDAQ:ZYXI) Suggests It's 22% UndervaluedDecember 18, 2024 | uk.finance.yahoo.comZynex partners with VA to offer pain management solutions for veteransDecember 17, 2024 | proactiveinvestors.comZynex Announces Partnership To Conduct Business with Veterans Affairs (VA) Medical Centers, the Largest Healthcare Network in the United StatesDecember 17, 2024 | prnewswire.comZynex CEO outlines plans for 2025 after revenue milestone – ICYMIDecember 13, 2024 | proactiveinvestors.comZynex CEO outlines plans for 2025 after revenue milestone – ICYMIDecember 13, 2024 | proactiveinvestors.comZynex UCSF Study Results Demonstrate Laser Technology Benefits in Resolving Racial Bias of Current LED Pulse OximetersDecember 12, 2024 | prnewswire.comZynex completes clinical verification trial of pulse oximeterDecember 7, 2024 | msn.comAnalysts Are Bullish on These Healthcare Stocks: Zynex (ZYXI), KalVista Pharmaceuticals (KALV)December 6, 2024 | markets.businessinsider.comZynex's (ZYXI) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $17.00 price target on shares of Zynex in a research note on Friday.December 6, 2024 | marketbeat.comHotchkis & Wiley Capital Management LLC Grows Stock Holdings in Zynex, Inc. (NASDAQ:ZYXI)Hotchkis & Wiley Capital Management LLC grew its holdings in shares of Zynex, Inc. (NASDAQ:ZYXI - Free Report) by 24.7% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 746,380 shares of the company's stock after purchasing an additional 147,770 shares duringDecember 6, 2024 | marketbeat.comZynex completes laser pulse oximetry trialDecember 6, 2024 | markets.businessinsider.comZynex Announces Completion of Its Laser Pulse Oximetry TrialDecember 5, 2024 | prnewswire.comZynex joins Open Oximetry Project as it advances innovative NiCO pulse oximeterDecember 3, 2024 | proactiveinvestors.comZynex Announces Open Oximetry Project MembershipDecember 3, 2024 | prnewswire.comZynex is an innovative medical technology company specializing in non-invasive pain management devicesNovember 28, 2024 | proactiveinvestors.com.auZynex leverages multi-modality NexWave device to transform pain managementNovember 26, 2024 | proactiveinvestors.comInsider Selling: Zynex, Inc. (NASDAQ:ZYXI) CEO Sells 2,000 Shares of StockNovember 14, 2024 | insidertrades.comZynex, Inc. (NASDAQ:ZYXI) CEO Thomas Sandgaard Sells 2,000 SharesNovember 7, 2024 | insidertrades.comZynex, Inc. (NASDAQ:ZYXI) CFO Daniel J. Moorhead Sells 10,000 SharesZynex, Inc. (NASDAQ:ZYXI - Get Free Report) CFO Daniel J. Moorhead sold 10,000 shares of the business's stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $8.59, for a total transaction of $85,900.00. Following the sale, the chief financial officer now owns 44,878 shares of the company's stock, valued at $385,502.02. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.November 4, 2024 | marketbeat.comZynex, Inc. (NASDAQ:ZYXI) CEO Thomas Sandgaard Sells 2,000 SharesNovember 2, 2024 | insidertrades.comZynex's (NASDAQ:ZYXI) Soft Earnings Are Actually Better Than They AppearOctober 31, 2024 | finance.yahoo.comZynex Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagOctober 26, 2024 | finance.yahoo.comZynex, Inc. (NASDAQ:ZYXI) Q3 2024 Earnings Call TranscriptOctober 26, 2024 | msn.comRBC Capital Keeps Their Buy Rating on Zynex (ZYXI)October 25, 2024 | markets.businessinsider.comZynex sees 2024 EPS at least 20c, consensus 20cOctober 25, 2024 | markets.businessinsider.comZynex (NASDAQ:ZYXI) Announces Quarterly Earnings ResultsZynex (NASDAQ:ZYXI - Get Free Report) issued its quarterly earnings results on Thursday. The company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.01. The company had revenue of $49.97 million for the quarter, compared to analyst estimates of $50.83 million. Zynex had a return on equity of 14.15% and a net margin of 3.12%. The company's revenue for the quarter was up .1% compared to the same quarter last year. During the same quarter last year, the company posted $0.10 EPS.October 25, 2024 | marketbeat.comZynex’s Strong Financial Performance and Strategic Growth Initiatives Justify Buy RatingOctober 25, 2024 | markets.businessinsider.comZynex price target raised to $17 from $16 at H.C. WainwrightOctober 25, 2024 | markets.businessinsider.comZynex (NASDAQ:ZYXI) Price Target Raised to $17.00 at HC WainwrightHC Wainwright increased their price target on shares of Zynex from $16.00 to $17.00 and gave the stock a "buy" rating in a research report on Friday.October 25, 2024 | marketbeat.comZynex Inc (ZYXI) Q3 2024 Earnings Call Highlights: Navigating Growth and ChallengesOctober 25, 2024 | finance.yahoo.comZynex, Inc. (ZYXI) Q3 2024 Earnings Call TranscriptOctober 25, 2024 | seekingalpha.comZynex (NASDAQ:ZYXI) Updates FY 2024 Earnings GuidanceZynex (NASDAQ:ZYXI) updated its FY 2024 earnings guidance. The company provided EPS guidance of 0.200- for the period, compared to the consensus estimate of 0.200. The company also issued revenue guidance of $200.0 millionillion-, compared to the consensus estimate of $200.5 millionillion.October 24, 2024 | marketbeat.comZynex sees pain management orders increase in Q3 following FDA approvalOctober 24, 2024 | proactiveinvestors.comZynex Reports Third Quarter 2024 Financial ResultsOctober 24, 2024 | prnewswire.comSales, strategy, and saving lives: A conversation with Zynex CEO Thomas SandgaardOctober 24, 2024 | proactiveinvestors.comZynex Sets Third Quarter 2024 Earnings CallOctober 16, 2024 | prnewswire.comAQR Capital Management LLC Sells 67,148 Shares of Zynex, Inc. (NASDAQ:ZYXI)AQR Capital Management LLC lowered its position in shares of Zynex, Inc. (NASDAQ:ZYXI - Free Report) by 63.0% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 39,439 shares of the company's stock after seOctober 16, 2024 | marketbeat.comMillennium Management LLC Acquires 118,615 Shares of Zynex, Inc. (NASDAQ:ZYXI)Millennium Management LLC increased its holdings in shares of Zynex, Inc. (NASDAQ:ZYXI - Free Report) by 66.5% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 297,082 shares of the company's stock afOctober 15, 2024 | marketbeat.comZynex, Inc.: 2025 Looks Like A Brighter YearOctober 10, 2024 | seekingalpha.comZynex price target lowered to $11 from $12 at RBC CapitalOctober 9, 2024 | finance.yahoo.comZynex (NASDAQ:ZYXI) Given New $11.00 Price Target at Royal Bank of CanadaRoyal Bank of Canada reduced their price target on Zynex from $12.00 to $11.00 and set an "outperform" rating for the company in a research report on Tuesday.October 8, 2024 | marketbeat.comZynex (NASDAQ:ZYXI) Stock Quotes, Forecast and News SummaryOctober 6, 2024 | benzinga.comRenaissance Technologies LLC Raises Position in Zynex, Inc. (NASDAQ:ZYXI)Renaissance Technologies LLC increased its holdings in shares of Zynex, Inc. (NASDAQ:ZYXI - Free Report) by 68.7% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 189,762 shares of the company's stock afOctober 4, 2024 | marketbeat.comInvestors in Zynex (NASDAQ:ZYXI) have unfortunately lost 22% over the last five yearsOctober 3, 2024 | finance.yahoo.comZynex's strategic shifts set stage for long-term success, analysts saySeptember 16, 2024 | proactiveinvestors.comZynex CEO reflects on 28 years of medical device innovation - ICYMISeptember 7, 2024 | proactiveinvestors.com Get Zynex News Delivered to You Automatically Sign up to receive the latest news and ratings for ZYXI and its competitors with MarketBeat's FREE daily newsletter. Email Address ZYXI Media Mentions By Week ZYXI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ZYXI News Sentiment▼1.440.69▲Average Medical News Sentiment ZYXI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ZYXI Articles This Week▼22▲ZYXI Articles Average Week Get Zynex News Delivered to You Automatically Sign up to receive the latest news and ratings for ZYXI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Paragon 28 News Establishment Labs News National Vision News Bioventus News CeriBell News AxoGen News Avanos Medical News Butterfly Network News Iradimed News SI-BONE News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ZYXI) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump vs. TexasEver since Donald Trump won the election, U.S. states have been rushing to pass new currency rules. These r...Stansberry Research | SponsoredTurning Panic Into OpportunityAI stocks were hammered on Jan. 27. That includes Nvidia, the undisputed leader in the artificial intellige...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zynex, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zynex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
